Autopsy report · NCT06236308

TTAX03 for the Treatment of Lumbosacral Facet Joint Pain

“Study was stopped due to reprioritization for active studies”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

BioTissue Holdings, Inc

Sponsor type

Industry

Conditions

Facet Joint Pain

Interventions

TTAX03 10mg; TTAX03 25mg; Placebo Comparator: Control Saline

Participants

0

Trials that died the same way

• Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer
  “Study stopped due to low accrual.” (73% match in meaning)
• Sorafenib-induced Hand- Foot Skin Reaction Treatment
  “Study was halted due to poor subject accrual.” (73% match in meaning)
• Inotropic Treatment With Levosimendan (SimdaxR)in Heart Surgery
  “The study was stopped due to difficulties in including patients” (73% match in meaning)
• Assessment of Pulmonary Congestion During Cardiac Hemodynamic Stress Testing
  “Study was stopped due to funding and time constraints.” (72% match in meaning)
• A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression
  “Study stopped due to lack of efficacy \& funding.” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.